Aclaris Therapeutics ACRS Royalty — Contract With Customer Liability Noncurrent

Similar metrics at other companies

ANFRoyalty — Contract with Customer, Liability, Current

$34.31M+3.8%

NUVBRoyalty Revenue — Deferred Revenue

$300K—

NTRARoyalty — Deferred Revenue

$500K-64.3%

OMERRoyalty Obligation Noncurrent

$141.93M-25.3%

OMERRoyalty Obligation Current

$19.86M-5.8%

CEVARoyalty — Contract With Customer Asset Net Current

$9.16M+8.3%

Questions, answered.

What is Aclaris Therapeutics's royalty — contract with customer liability noncurrent?

Aclaris Therapeutics (ACRS) reported royalty — contract with customer liability noncurrent of $15.3M in Q1 2026.

How has Aclaris Therapeutics's royalty — contract with customer liability noncurrent changed year-over-year?

Aclaris Therapeutics's royalty — contract with customer liability noncurrent decreased by 20.3% year-over-year, from $19.2M to $15.3M.

What does royalty — contract with customer liability noncurrent mean?

This represents the long-term portion of deferred revenue or performance obligations arising from royalty contracts that will be satisfied beyond the next fiscal year. It indicates the company's future obligations to provide services or rights associated with royalty-bearing intellectual property. A significant balance suggests a long-term commitment to partners or licensees that will be recognized as revenue over an extended period.